#obesity-treatment

#obesity-treatment

If there has been a hot topic in health in 2025, it's definitely been GLP-1s, colloquially referred to as anti-obesity jabs. These medications, taken weekly as an injection into the abdomen, result in significant weight loss and, despite being developed to manage type 2 diabetes in those with metabolic disorders, have become mainstream in many countries as a treatment for obesity.

Your donation allows us to keep sending journalists to speak to both sides of the story. The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.Your support makes all the difference.

The future of medicine will be personalized, taking patients' specific medical history into account when prescribing care. Hand-tailored treatment plans are especially crucial for issues as nuanced as obesity.

A study has been launched due to reports of serious side effects related to weight loss drugs potentially affecting the pancreas, prompting safety investigations.

Sheree's struggle emphasizes the increasing reliance on non-traditional methods for weight management amidst the challenges presented by GLP-1 therapies.

Pfizer's decision to halt danuglipron development underscores the risks and complexities involved in creating new obesity treatments, particularly after significant financial investment and testing phases.